CA2067648A1 - Octahydrobenzo[g]quinoline - Google Patents
Octahydrobenzo[g]quinolineInfo
- Publication number
- CA2067648A1 CA2067648A1 CA002067648A CA2067648A CA2067648A1 CA 2067648 A1 CA2067648 A1 CA 2067648A1 CA 002067648 A CA002067648 A CA 002067648A CA 2067648 A CA2067648 A CA 2067648A CA 2067648 A1 CA2067648 A1 CA 2067648A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- acid addition
- free base
- addition salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ABSTRACT
The invention relates to the compound of formula I
The invention relates to the compound of formula I
Description
OCTAHYDROBENZO[G]QUINOLINE
The present invention relates to a new octahydro[glquinoline, its production and its use in therapy.
The compound of the invention is the (-)-(3~,4a,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridylthio)methyl]-1-methyl-6-hydroxy-benzolg]quinoline of formula I
¦ ~H (I) HO ~
in free base form or in acid addition salt form.
Structurally related compounds are known from European Patent No. 77754. However, the compound of formula I has never been specifi-cally disclosed. It has now surprisingly been found that this compound exhibits a particularly interesting pharmacological activity profile.
In accordance with the invention, the compound of formula I and its acid addition salts are obtained by methylating the compound of formula II
The present invention relates to a new octahydro[glquinoline, its production and its use in therapy.
The compound of the invention is the (-)-(3~,4a,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridylthio)methyl]-1-methyl-6-hydroxy-benzolg]quinoline of formula I
¦ ~H (I) HO ~
in free base form or in acid addition salt form.
Structurally related compounds are known from European Patent No. 77754. However, the compound of formula I has never been specifi-cally disclosed. It has now surprisingly been found that this compound exhibits a particularly interesting pharmacological activity profile.
In accordance with the invention, the compound of formula I and its acid addition salts are obtained by methylating the compound of formula II
~S~
H,~, H
I I H (II) H0 ~
and if desired, converting the compound obtained into its acid addition salts.
The process according to the invention may be carried out by known methods, for example using formaldehyde/NaBH4, as described in the following example under e).
Working up of the reaction mixture obtained and purification of the compound of formula I thus produced may be carried out by known methods.
Acid addition salts can be produced from the free bases in known manner, and vice versa.
The starting compound of formula II may be prepared from the compound of formula VII in accordance with the following reaction scheme, for example as described in the example under a~ to d):
` 2~67648 ls ~ S
(-) ~ HOCH3 (~) H ~ HOCH3 CH30 ~ ~ ~ CH30 VII VI
Ms = mesyl Zn/AcOH 1 ~, D ,~C1 ~, O
Konz. HCl separation by fractional crystallization ~S~
(-) ~ NH
CH3 ~ ~ H HBr II
III
20676~8 The starting compound of formula VII is known from literature.
The compound of formula I and its physiologically acceptable acid addition salts, referred to hereinafter as compounds according to the invention, exhibit interesting pharmacological activities in animal tests and may therefore be used as pharmaceuticals.
The compounds according to the invention have in particular dopaminergic activity in vivo on the central nervous system, which is detected by contra-lateral rotation when administered at doses of 1 to 20 mg/kg p.o. or 0.1 to 0.3 mg/kg s.c. to rats which have undergone unilateral lesions in the nigrostriatal dopamine tract through a 6-hydroxy-dopamine injection [U. Ungerstedt, Acta physiol. scand.
Suppl. 367, 69 - 93 (1973)].
The compounds according to the invention can therefore be used as dopaminergic agents, e.g. in the treatment of Parkinson's disease.
Furthermore, the compounds according to the invention effect a decrease on the intra-ocular pressure in rabbits, at concentrations of 10 to 100 ~M. Hale rabbits of ca. 2'k kg are fixed in cages leaving their heads free. The solutions with the compound to be tested are applied to the right eye and the placebo solutions to the left eye (2 drops each, i.e. ca. 40 ~l). The eyes are firstly anaesthetized with a solution containing Novesine (0.4 %) and Fluorescein (0.05 %) and the ocular pressure is determined at various intervals after administration tlO, 20, 30, 60, 90, 120, 180 and 240 minutes), whereby an applanation tonometer according to Goldberg is used.
The compounds according to the invention are therefore useful in the treatment of glaucoma.
H,~, H
I I H (II) H0 ~
and if desired, converting the compound obtained into its acid addition salts.
The process according to the invention may be carried out by known methods, for example using formaldehyde/NaBH4, as described in the following example under e).
Working up of the reaction mixture obtained and purification of the compound of formula I thus produced may be carried out by known methods.
Acid addition salts can be produced from the free bases in known manner, and vice versa.
The starting compound of formula II may be prepared from the compound of formula VII in accordance with the following reaction scheme, for example as described in the example under a~ to d):
` 2~67648 ls ~ S
(-) ~ HOCH3 (~) H ~ HOCH3 CH30 ~ ~ ~ CH30 VII VI
Ms = mesyl Zn/AcOH 1 ~, D ,~C1 ~, O
Konz. HCl separation by fractional crystallization ~S~
(-) ~ NH
CH3 ~ ~ H HBr II
III
20676~8 The starting compound of formula VII is known from literature.
The compound of formula I and its physiologically acceptable acid addition salts, referred to hereinafter as compounds according to the invention, exhibit interesting pharmacological activities in animal tests and may therefore be used as pharmaceuticals.
The compounds according to the invention have in particular dopaminergic activity in vivo on the central nervous system, which is detected by contra-lateral rotation when administered at doses of 1 to 20 mg/kg p.o. or 0.1 to 0.3 mg/kg s.c. to rats which have undergone unilateral lesions in the nigrostriatal dopamine tract through a 6-hydroxy-dopamine injection [U. Ungerstedt, Acta physiol. scand.
Suppl. 367, 69 - 93 (1973)].
The compounds according to the invention can therefore be used as dopaminergic agents, e.g. in the treatment of Parkinson's disease.
Furthermore, the compounds according to the invention effect a decrease on the intra-ocular pressure in rabbits, at concentrations of 10 to 100 ~M. Hale rabbits of ca. 2'k kg are fixed in cages leaving their heads free. The solutions with the compound to be tested are applied to the right eye and the placebo solutions to the left eye (2 drops each, i.e. ca. 40 ~l). The eyes are firstly anaesthetized with a solution containing Novesine (0.4 %) and Fluorescein (0.05 %) and the ocular pressure is determined at various intervals after administration tlO, 20, 30, 60, 90, 120, 180 and 240 minutes), whereby an applanation tonometer according to Goldberg is used.
The compounds according to the invention are therefore useful in the treatment of glaucoma.
The ccmpounds according to the invention also show activity in the behavioural despair test [R.D. Porsolt et al., Arch. Int. Pharmaco-dyn., 229, 327 - 336 (1977)] upon administering doses of 10 to 100 mg/kg p.o.
The compounds for use according to the invention are therefore useful as antidepressants.
In addition, the compounds according to the invention effect an inhibition of the dependency on cocaine when administered at doses of 0.1 to 10 mg/kg p.o. ~o monkeys which administer the drug themselves according to the method described in Psychopharmacologia (Berl.) 16, 30 - 48 (1969).
The compounds according to the invention may therefore be used in the prevention, reduction or treatment of dependency (or for treatment after deprivation to avoid renewed dependency) arising from the abuse of cocaine.
For these therapeutical activities, an indicated daily dosage lies in the range ca. 1 to 100 mg, especially ca. 10 to 80 mg, of the compound according to the invention, which is conveniently administered e.g. in part doses up to 4 times daily.
The compounds according to the invention may be administered in any usual manner, e.g. orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injection solutions or suspensions.
For the treatment of glaucoma, the compounds according to the invention are preferably applied topically to the eye in ca. 0.002 to ca. 0.02 % ophthalmological solutions.
2~676~8 In accordance with the foregoing, the present invention also provides a compound according to the invention, for use as a pharmaceutical, e.g. for the treatment of glaucoma, depression, cocaine dependency or Morbus Parkinson.
The present invention furthermore provides a pharmaceutical composition comprising a compound according to the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner.
In the following example, all temperatures are uncorrected and are in degrees Centigrade.
20676~8 EXAMPLE: (-)-(3~,4aa,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-1(2-pyridylthio)methyl]-l-methyl-6-hydroxy-benzolg]quinoline a) (+)-(3~,4aa,10aO-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyl]-1,6-dimethoxy-benzolglquinoline A solution of 11 g (30.9 mM) of (+)-(3~,4aa,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-mesyloxymethyl-1,6-dimethoxy-benzo[g]quinoline and 11 g (100 mM) of 2-mercaptopyridine in 200 ml of dimethylformamide is mixed at 10 - 15 with 41 ml of 2 N
NaOH and stirred at room temperature for 20 hours. The suspension is worked by by concentrating in a rotary evaporator, mixing with water and extracting with methylene chloride. The organic phases are dried over Na2SO4, filtered and concentrated. Chromatography on silical gel with methylene chloride/3% ethanol yields 5.6 g of the title compound (49% of theory).
NMR (CDCl3, 360 MHz) ~ 0.94 (q, J = 12 ~z, H-C9aX), 2.74 (dd, J1 =
12 Hz, J2 = 18 Hz, H-C5aX), 3.61 (s, N-OCH3), 3.8 (s, C-OCH3).
b) (~)-(3~,4a,10aO-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyll-6-methoxy-benzo[glquinoline 10 g (27 mM) of the compound obtained under a) and 37.8 g (570 mM) of zinc are suspended in a solution of 55 ml of water and 110 ml of acetic acid and stirred at room temperature for 20 hours. The suspension is filtered through Hyflo, concentrated, adjusted to pH
7 - 8 with 2 N NaOH and extracted with methylene chloride. After drying over Na2SO4, filtering and concentrating on a rotary evaporator, 8 g of crude product are obtained as a yellow oil, and this is chromatographed on silica gel with methylene chloride/2.5%
methanol: 4.6 g of the title compound (50~ of theory) are thereby obtained as a yellowish oil.
206764~
The compounds for use according to the invention are therefore useful as antidepressants.
In addition, the compounds according to the invention effect an inhibition of the dependency on cocaine when administered at doses of 0.1 to 10 mg/kg p.o. ~o monkeys which administer the drug themselves according to the method described in Psychopharmacologia (Berl.) 16, 30 - 48 (1969).
The compounds according to the invention may therefore be used in the prevention, reduction or treatment of dependency (or for treatment after deprivation to avoid renewed dependency) arising from the abuse of cocaine.
For these therapeutical activities, an indicated daily dosage lies in the range ca. 1 to 100 mg, especially ca. 10 to 80 mg, of the compound according to the invention, which is conveniently administered e.g. in part doses up to 4 times daily.
The compounds according to the invention may be administered in any usual manner, e.g. orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injection solutions or suspensions.
For the treatment of glaucoma, the compounds according to the invention are preferably applied topically to the eye in ca. 0.002 to ca. 0.02 % ophthalmological solutions.
2~676~8 In accordance with the foregoing, the present invention also provides a compound according to the invention, for use as a pharmaceutical, e.g. for the treatment of glaucoma, depression, cocaine dependency or Morbus Parkinson.
The present invention furthermore provides a pharmaceutical composition comprising a compound according to the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner.
In the following example, all temperatures are uncorrected and are in degrees Centigrade.
20676~8 EXAMPLE: (-)-(3~,4aa,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-1(2-pyridylthio)methyl]-l-methyl-6-hydroxy-benzolg]quinoline a) (+)-(3~,4aa,10aO-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyl]-1,6-dimethoxy-benzolglquinoline A solution of 11 g (30.9 mM) of (+)-(3~,4aa,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-mesyloxymethyl-1,6-dimethoxy-benzo[g]quinoline and 11 g (100 mM) of 2-mercaptopyridine in 200 ml of dimethylformamide is mixed at 10 - 15 with 41 ml of 2 N
NaOH and stirred at room temperature for 20 hours. The suspension is worked by by concentrating in a rotary evaporator, mixing with water and extracting with methylene chloride. The organic phases are dried over Na2SO4, filtered and concentrated. Chromatography on silical gel with methylene chloride/3% ethanol yields 5.6 g of the title compound (49% of theory).
NMR (CDCl3, 360 MHz) ~ 0.94 (q, J = 12 ~z, H-C9aX), 2.74 (dd, J1 =
12 Hz, J2 = 18 Hz, H-C5aX), 3.61 (s, N-OCH3), 3.8 (s, C-OCH3).
b) (~)-(3~,4a,10aO-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyll-6-methoxy-benzo[glquinoline 10 g (27 mM) of the compound obtained under a) and 37.8 g (570 mM) of zinc are suspended in a solution of 55 ml of water and 110 ml of acetic acid and stirred at room temperature for 20 hours. The suspension is filtered through Hyflo, concentrated, adjusted to pH
7 - 8 with 2 N NaOH and extracted with methylene chloride. After drying over Na2SO4, filtering and concentrating on a rotary evaporator, 8 g of crude product are obtained as a yellow oil, and this is chromatographed on silica gel with methylene chloride/2.5%
methanol: 4.6 g of the title compound (50~ of theory) are thereby obtained as a yellowish oil.
206764~
NMR (CDCl3, 360 MHz) ~ 1.03 (q, J = 12 Hz, H-C9aX), 2.67 (t, J =
12, H-C5aX), 2.88 (b, N-H), 3.8 (s, C-OCH3).
c) (-)-(3,C,4ao~,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-1(2-pyridyl-thio)methyl]-6-methoxy-benzolglquinoline In order to split the racemate, the racemic sec. amine obtained under b) is converted using (-)-camphanic acid chloride into the two diastereoisomeric amides, which are separated by fractional crystallization from diisopropyl ether. The two diastereoisomeric amides possess the following rotational values (CHC13): [alD20 =
- 108 resp. [alD20 = + 86. In order to carry out amide hydrolysis, 3.4 g (6.5 mM) of the amide with [~1D20 = - 108 are stirred for 16 hours at 105 in 135 ml of conc. HCl, diluted with water, neutralized at 10 with 10 N NaOH and extracted with methylene chloride/10% isopropanol. The organic phases are dried with Na2SO4, filtered and concentrated on a rotary evaporator. The yield is 2 g of crude product, which is chromatographed on silica gel with methylene chloride/7% methanol. The resulting 1.6 g of pure enantiomer are used further without characterization.
d) (-)-(3~,4a~,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyl]-6-hydroxy-benzolg]quinoline 1.6 g (4.7 mM) of the pure enantiomer obtained under c) in 14 ml of HBr (47%) are stirred for 6 hours at 100. The mixture is subsequently concentrated, neutralized with 2 N NaOH and extracted with methylene chloride/10% isopropanol. After drying over Na2SO4, filtering and concentrating by evaporation, 1.8 g of crude hydroxy derivative are obtained, which is chromatographed on silica gel with methylene chloride/7% methanol. The resulting 1 g of pure hydroxy derivative is immediately N-methylated.
20676~8 e) (-)-(3~,4a~,10aO-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyl]-l-methyl-6-hydroxy-benzolg]quinoline A solution of 1 g (3.06 mM) of the hydroxy derivative obtained under d) and 8 ml of aqueous 35% formaldehyde solution in 80 ml of methanol is stirred for 30 minutes at room temperature, and subsequently mixed slowly in portions at 0 with 2.2 g of NaBH4.
After stirring for 2 hours at room temperature, it is concentrated, mixed with NaHC03 solution and extracted with chloroform. Drying over Na2S04, filtering and concentrating by evaporation yield 1 g (99% of theory) of pure title compound, which is crystallized from acetone/ethyl acetate: la]D20 = _ 162 (pyridine). Following recrystallization from acetone/ethyl acetate: [~]D20 = -160 (pyridine). M.p. - 186 - 187.
12, H-C5aX), 2.88 (b, N-H), 3.8 (s, C-OCH3).
c) (-)-(3,C,4ao~,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-1(2-pyridyl-thio)methyl]-6-methoxy-benzolglquinoline In order to split the racemate, the racemic sec. amine obtained under b) is converted using (-)-camphanic acid chloride into the two diastereoisomeric amides, which are separated by fractional crystallization from diisopropyl ether. The two diastereoisomeric amides possess the following rotational values (CHC13): [alD20 =
- 108 resp. [alD20 = + 86. In order to carry out amide hydrolysis, 3.4 g (6.5 mM) of the amide with [~1D20 = - 108 are stirred for 16 hours at 105 in 135 ml of conc. HCl, diluted with water, neutralized at 10 with 10 N NaOH and extracted with methylene chloride/10% isopropanol. The organic phases are dried with Na2SO4, filtered and concentrated on a rotary evaporator. The yield is 2 g of crude product, which is chromatographed on silica gel with methylene chloride/7% methanol. The resulting 1.6 g of pure enantiomer are used further without characterization.
d) (-)-(3~,4a~,10a~)-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyl]-6-hydroxy-benzolg]quinoline 1.6 g (4.7 mM) of the pure enantiomer obtained under c) in 14 ml of HBr (47%) are stirred for 6 hours at 100. The mixture is subsequently concentrated, neutralized with 2 N NaOH and extracted with methylene chloride/10% isopropanol. After drying over Na2SO4, filtering and concentrating by evaporation, 1.8 g of crude hydroxy derivative are obtained, which is chromatographed on silica gel with methylene chloride/7% methanol. The resulting 1 g of pure hydroxy derivative is immediately N-methylated.
20676~8 e) (-)-(3~,4a~,10aO-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridyl-thio)methyl]-l-methyl-6-hydroxy-benzolg]quinoline A solution of 1 g (3.06 mM) of the hydroxy derivative obtained under d) and 8 ml of aqueous 35% formaldehyde solution in 80 ml of methanol is stirred for 30 minutes at room temperature, and subsequently mixed slowly in portions at 0 with 2.2 g of NaBH4.
After stirring for 2 hours at room temperature, it is concentrated, mixed with NaHC03 solution and extracted with chloroform. Drying over Na2S04, filtering and concentrating by evaporation yield 1 g (99% of theory) of pure title compound, which is crystallized from acetone/ethyl acetate: la]D20 = _ 162 (pyridine). Following recrystallization from acetone/ethyl acetate: [~]D20 = -160 (pyridine). M.p. - 186 - 187.
Claims (10)
1. A process for the production of the (-)-(3.beta.,4a.alpha.,10a.beta.)-1,2,3,4,4a,5,10,10a-octahydro-3-[(2-pyridylthio)methyl]-1-methyl-6-hydroxy-benzo[g]quinoline of formula I
(-) (I) in free base form or in acid addition salt form, which includes the step of methylating the compound of formula II
(-) (II) and, if desired, converting the compound obtained into its acid addition salts.
(-) (I) in free base form or in acid addition salt form, which includes the step of methylating the compound of formula II
(-) (II) and, if desired, converting the compound obtained into its acid addition salts.
2. A process for the production of the compound of formula I in free base or acid addition salt form, substantially as hereinbefore described with reference to the example.
3. A compound of formula I in free base or acid addition salt form, whenever produced by the process of claim 1.
4. A compound of formula I in free base or acid addition salt form, as defined in claim 1.
5. A compound of claim 4 in free base form.
6. A compound of claim 4 in form of the hydrochloride.
7. A compound of any one of claims 3 to 6 in physiologically acceptable form, for use as a pharmaceutical.
8. A compound of any one of claims 3 to 6 in physiologically acceptable form, for use in the treatment of Morbus Parkinson, depression or cocaine dependency.
9. A compound of any one of claims 3 to 6 in physiologically acceptable form, for use in the treatment of glaucoma.
10. A pharmaceutical composition comprising a compound according to any one of claims 3 to 6 in physiologically acceptable form, in association with a pharmaceutical carrier or diluent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4114325.6 | 1991-05-02 | ||
| DE4114325A DE4114325A1 (en) | 1991-05-02 | 1991-05-02 | OCTAHYDROBENZO (G) QUINOLINE, ITS PRODUCTION AND USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2067648A1 true CA2067648A1 (en) | 1992-11-03 |
Family
ID=6430818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002067648A Abandoned CA2067648A1 (en) | 1991-05-02 | 1992-04-30 | Octahydrobenzo[g]quinoline |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP0512952A1 (en) |
| JP (1) | JPH05170762A (en) |
| KR (1) | KR920021533A (en) |
| AU (1) | AU656768B2 (en) |
| CA (1) | CA2067648A1 (en) |
| CS (1) | CS131192A3 (en) |
| DE (1) | DE4114325A1 (en) |
| FI (1) | FI921957A (en) |
| HU (1) | HUT61011A (en) |
| IE (1) | IE921374A1 (en) |
| IL (1) | IL101735A0 (en) |
| MX (1) | MX9202024A (en) |
| MY (1) | MY131278A (en) |
| NO (1) | NO921723L (en) |
| NZ (1) | NZ242562A (en) |
| RO (1) | RO109333B1 (en) |
| TW (1) | TW241262B (en) |
| ZA (1) | ZA923187B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9326010D0 (en) * | 1993-12-21 | 1994-02-23 | Sandoz Ltd | Improvements in or relating to organic compounds |
| TW378209B (en) * | 1996-07-08 | 2000-01-01 | Novartis Ag | Benzo[g]quinoline derivatives, their preparation and the pharmaceutical composition containing them |
| SE0001438D0 (en) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| PE20030240A1 (en) * | 2001-07-09 | 2003-04-16 | Novartis Ag | BENZO DERIVATIVES [g] QUINOLINE |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE56958T1 (en) * | 1981-10-16 | 1990-10-15 | Sandoz Ag | 1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO(G)QUINOLINE DERIVATIVES WITH PHARMACEUTICAL ACTIVITIES. |
| PH22782A (en) * | 1983-02-01 | 1988-12-12 | Sandoz Ltd | Novel pharmaceutical active 1,2,3,4,4a,5,10,10a octahydrobenzo(g)quinoline derivatives |
-
1991
- 1991-05-02 DE DE4114325A patent/DE4114325A1/en not_active Withdrawn
-
1992
- 1992-04-16 HU HU9201296A patent/HUT61011A/en unknown
- 1992-04-28 MY MYPI92000725A patent/MY131278A/en unknown
- 1992-04-28 EP EP92810306A patent/EP0512952A1/en not_active Withdrawn
- 1992-04-29 CS CS921311A patent/CS131192A3/en unknown
- 1992-04-30 IL IL101735A patent/IL101735A0/en unknown
- 1992-04-30 RO RO92-200596A patent/RO109333B1/en unknown
- 1992-04-30 AU AU15291/92A patent/AU656768B2/en not_active Ceased
- 1992-04-30 NO NO92921723A patent/NO921723L/en unknown
- 1992-04-30 CA CA002067648A patent/CA2067648A1/en not_active Abandoned
- 1992-04-30 KR KR1019920007312A patent/KR920021533A/en not_active Application Discontinuation
- 1992-04-30 NZ NZ242562A patent/NZ242562A/en unknown
- 1992-04-30 ZA ZA923187A patent/ZA923187B/en unknown
- 1992-04-30 MX MX9202024A patent/MX9202024A/en unknown
- 1992-04-30 FI FI921957A patent/FI921957A/en not_active Application Discontinuation
- 1992-05-01 JP JP4112524A patent/JPH05170762A/en active Pending
- 1992-05-04 TW TW081103467A patent/TW241262B/zh active
- 1992-07-01 IE IE137492A patent/IE921374A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR920021533A (en) | 1992-12-18 |
| IL101735A0 (en) | 1992-12-30 |
| ZA923187B (en) | 1993-11-01 |
| HUT61011A (en) | 1992-11-30 |
| DE4114325A1 (en) | 1992-11-05 |
| NO921723D0 (en) | 1992-04-30 |
| AU1529192A (en) | 1992-11-05 |
| EP0512952A1 (en) | 1992-11-11 |
| TW241262B (en) | 1995-02-21 |
| MY131278A (en) | 2007-07-31 |
| CS131192A3 (en) | 1992-11-18 |
| NZ242562A (en) | 1994-08-26 |
| HU9201296D0 (en) | 1992-07-28 |
| JPH05170762A (en) | 1993-07-09 |
| RO109333B1 (en) | 1995-01-30 |
| FI921957A (en) | 1992-11-03 |
| FI921957A0 (en) | 1992-04-30 |
| IE921374A1 (en) | 1992-11-04 |
| NO921723L (en) | 1992-11-03 |
| MX9202024A (en) | 1992-11-01 |
| AU656768B2 (en) | 1995-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3418270A1 (en) | NEW AMINOTETRAL DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF | |
| DK164557B (en) | DERIVATIVES OF CIS, ENDO-2-AZABICYCLO-OE5.3.0AA-DECAN-3-CARBOXYLIC ACID AND MEDICINAL CONTAINING THEM | |
| HU229794B1 (en) | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use and pharmaceutical compositions containing them | |
| DD209833A5 (en) | METHOD OF PREPARING BENZOAZACYCLOALKYL SPIRO-IMIDAZOLIDINES | |
| KR940003071B1 (en) | Benzoxazine derivatives and process for preparaing thereof | |
| US5807897A (en) | Aminotetralin derivative and compositions and method of use thereof | |
| US4134991A (en) | Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid | |
| US20100069450A1 (en) | Salt of 3-benzyl-2-methyl-2,3,3a,4,5,6,7, 7a- octahydrobenzo[d]isoxazol-4-one | |
| CA2067648A1 (en) | Octahydrobenzo[g]quinoline | |
| US7105528B2 (en) | Benzo [g] quinoline derivatives for treating glaucoma and myopia | |
| US5262422A (en) | Octahydrobenzo[g]quinoline | |
| EP0146392A1 (en) | B-phenethanolamine antiobesity agents | |
| EP1480970B1 (en) | Quinoline derivatives | |
| AU2002328856A1 (en) | Benzo (G) quinoline derivatives for treating glaucoma and myopia | |
| US6057334A (en) | Benzo[g]quinoline derivatives | |
| DE69732359T2 (en) | DISUBSTITUTED MORPHOLIN, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | |
| FR2599033A1 (en) | 3- (HYDROXYMETHYL) -ISOQUINOLINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| EP0157762B1 (en) | New substituted piperidinoguanidines, preparation process and pharmaceutical compositions containing them | |
| EP0573391A1 (en) | Thiosemicarbazonic acid esters and their use as pharmaceuticals | |
| FR2607134A1 (en) | NOVEL DERIVATIVES OF OCTAHYDROBENZO (G) QUINOLINE, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | |
| IL103894A (en) | Benzoquinoxalines their production and pharmaceutical compositions containing them | |
| BE898221A (en) | Derivatives azepino (1,2-a) pyrimidine bronchodilators, their acid addition salts and pharmaceutical compositions containing them. | |
| CH635335A5 (en) | 2,3-Diphenylchromone derivatives, process for their preparation and their therapeutic application | |
| WO1999051577A1 (en) | (s)-2-(biphenyl-4-sulphonylamino)-3-(1h-indolyl)-propionic acid derivatives as matrix metal protein inhibitors | |
| PL167577B1 (en) | Method of obtaining novel octahydro/g/quinoline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |